Abstract | BACKGROUND: PATIENTS AND METHODS: Fifty two untreated patients with LA-SCCHN were enrolled in a chemoradiation feasibility study in the Oncology Department, Assuit University Hospital, between the time period from November 2006 to September 2008 of whom forty one patients were eligible for the study. The patients were randomized into 2 groups; group I (21 patients) who received paclitaxel 30mg/m2 I.V 1 hour infusion weekly and group II (20 patients) received Cisplatin 30mg/m2, I.V 2 hours infusion weekly, both during the course of radiation therapy. All patients received 66-70Gy concurrent radiation using a linear accelerator with 6mv photons, at the rate of 2Gy/day, 5 fractions/week, over a period of 6-7 weeks. Response was assessed according to WHO criteria and toxicity according to Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria and NCI-CTC version 2. RESULTS: Complete response was achieved in 57.1% of patients in group I and 50% of patients in group II while partial response was achieved in 28.6% in group I and 25% in group II. Thus, the objective overall response was 85.7% in group I versus 75% in group II with no statistically significant difference (p=0.3). The median duration of follow-up was 15 months in group I (range 9- 28 months) while it was 16.5 months for group II (range7- 29 months). The median progression free survival (PFS) was 26 months for group I and 22 months for group II. The 1-year PFS was 80.7% and 64% for group I and group II while the 2-year PFS were 52.2 and 41.1% for group I and group II respectively with no statistically significant difference (p=0.5). The median survival was 27 and 25 months for group I and II respectively. The1-year overall survival (OS) was 80.7% and 64.6% for group I and II while the 2-year OS was 58.4 and 46% for group I and group II respectively with no statistically significant difference (p=0.41). Treatment toxicities including skin reactions, mucositis and dysphagia were comparable in both groups and tolerable. CONCLUSION: KEY WORDS:
|
Authors | Hoda H Essa, Mohammed Azzam |
Journal | Journal of the Egyptian National Cancer Institute
(J Egypt Natl Canc Inst)
Vol. 22
Issue 3
Pg. 165-73
(Sep 2010)
ISSN: 1110-0362 [Print] England |
PMID | 21863067
(Publication Type: Journal Article)
|